| 摘要 |
Treatment of urinary incontinence in a female mammal comprises administration: (a) a nitric oxide synthase substrate (NOSS) and/or a nitric oxide donor (NOD), and optionally (b) a progestin, an oestrogen and/or a partial oestrogen agonist; and optionally (c) one or more of an ~a-adrenergic agonist, a ~b-receptor blocking agent, a cholinergic blocking agent and a cholinergic stimulating drug. Also claimed are compositions comprising (a) and optionally (b) and/or (c). The NOSS is L-arginine and the NOD is sodium nitroprusside, nitroglycerin, glyceryl trinitrate, SIN1, isosorbid mononitrate or isosorbid dinitrate. The amount of NOSS and/or NOD is effective to raise the blood level of circulating L-arginine to /-50-5000 microM above the normally circulating levels of 50-1000 microM, or raise NOD levels to 10 nM to 100 microM. For a non-pregnant female, (a) is administered with an oestrogen (preferably estradiol valerate, conjugated equine oestrogens, 17beta-estradiol, estrone or estriol), or partial oestrogen agonist (preferably raloxifen, centchroman or tamoxifen) or a progestin (preferably progesterone, dydrogesterone, medroxyprogesterone, norethisterone, levonorgestrel, norgestrel, gestodene or drospirenone). The amount of oestrogen is equivalent to 1-2 mg estradiol and the amount of progestin bioequivalent to 50-300 mg injected progesterone. |
